Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting
Journal of the National Comprehensive Cancer Network · 2026
DOI: 10.6004/jnccn.2025.7120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026. Verfasst von Sarah L Kerns und 11 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Radiation Oncology, The Medical College of Wisconsin, Milwaukee, WI. Hauptthemen laut MEDLINE: Testicular Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Renal Insufficiency. Die Arbeit nennt 146 Literaturangaben. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
This study aimed to quantify, for the first time, cumulative burden of morbidity (CBM) scores—including renal function—in long-term testicular cancer survivors (TCS) treated with contemporary NCCN-endorsed regimens of 4 cycles of etoposide/cisplatin (EPx4) or 3 or 4 cycles of bleomycin/etoposide/cisplatin (BEPx3/BEPx4). Patients and Methods: A total of 798 TCS underwent baseline clinical examinations and completed follow-up questionnaires. Severity grades for adverse health outcomes (AHOs) and CBM scores were calculated. Adjusted ordinal logistic regression estimated odds ratios (ORs) for AHOs and CBM scores by treatment regimen. Baseline estimated glomerular filtration rate (eGFR) was analyzed for associations with cumulative cisplatin dose and selected follow-up AHOs.
Results
Median age at follow-up was 45 years (median, 11 years postchemotherapy); 516 (65%) TCS survived ≥10 years. Chemotherapy consisted largely of BEPx3 (n=317; 39.7%), EPx4 (n=198; 24.8%), or BEPx4 (n=99; 12.4%); 27 (3.4%) received etoposide/ifosfamide/cisplatin (VIPx4). TCS receiving EPx4 (vs BEPx3) had significantly increased odds of worse renal impairment (adjusted OR [aOR], 1.55; P =.035), ototoxicity (aOR, 1.48; P =.04), and neuropathy (aOR, 1.77; P =.002). Reduced eGFR (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Department of Radiation Oncology, The Medical College of Wisconsin, Milwaukee, WI.
- 2Division of Medical Oncology, Indiana University School of Medicine, Indianapolis, IN.
- 3Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN.
- 4J.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
- 5Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA.
- 6Memorial Sloan Kettering Cancer Center, New York, NY.
Förderung
- NCI NIH HHS
Zitieren
APA
Kerns, S. L., Dinh, P. C., Monahan, P. O., Fung, C., Sesso, H. D., Feldman, D. R., Hamilton, R. J., Vaughn, D. J., Kollmannsberger, C., Martin, N. E., Einhorn, L. H., & Travis, L. B. (2026). Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2025.7120
Vancouver
Kerns SL, Dinh PC, Monahan PO, Fung C, Sesso HD, Feldman DR, et al. Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting. Journal of the National Comprehensive Cancer Network. 2026. doi:10.6004/jnccn.2025.7120
BibTeX
@article{Kerns2026,
author = {Kerns, Sarah L and Dinh, Paul C and Monahan, Patrick O and Fung, Chunkit and Sesso, Howard D and Feldman, Darren R and Hamilton, Robert J and Vaughn, David J and Kollmannsberger, Christian and Martin, Neil E and Einhorn, Lawrence H and Travis, Lois B},
title = {Renal Impairment and Late Toxicities Comparing Contemporary Chemotherapy Regimens for Testicular Cancer in a Real-World Setting},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
doi = {10.6004/jnccn.2025.7120}
}
EUVIMED